CL2024001157A1 - Formulación farmacéutica que comprende el anticuerpo monoclonal anti-ox40 - Google Patents

Formulación farmacéutica que comprende el anticuerpo monoclonal anti-ox40

Info

Publication number
CL2024001157A1
CL2024001157A1 CL2024001157A CL2024001157A CL2024001157A1 CL 2024001157 A1 CL2024001157 A1 CL 2024001157A1 CL 2024001157 A CL2024001157 A CL 2024001157A CL 2024001157 A CL2024001157 A CL 2024001157A CL 2024001157 A1 CL2024001157 A1 CL 2024001157A1
Authority
CL
Chile
Prior art keywords
pharmaceutical formulation
monoclonal antibody
disclosed
subpackaging
shipping
Prior art date
Application number
CL2024001157A
Other languages
English (en)
Spanish (es)
Inventor
Sun Qiang
Jin Xionghua
Fan Pengcheng
Xu Zhihao
Original Assignee
Inmagene Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inmagene Pte Ltd filed Critical Inmagene Pte Ltd
Publication of CL2024001157A1 publication Critical patent/CL2024001157A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CL2024001157A 2021-10-15 2024-04-12 Formulación farmacéutica que comprende el anticuerpo monoclonal anti-ox40 CL2024001157A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2021124200 2021-10-15
CN2022118065 2022-09-09

Publications (1)

Publication Number Publication Date
CL2024001157A1 true CL2024001157A1 (es) 2024-11-15

Family

ID=85987310

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2024001157A CL2024001157A1 (es) 2021-10-15 2024-04-12 Formulación farmacéutica que comprende el anticuerpo monoclonal anti-ox40

Country Status (13)

Country Link
US (1) US20250282882A1 (cg-RX-API-DMAC7.html)
EP (1) EP4415754A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024538140A (cg-RX-API-DMAC7.html)
KR (1) KR20240109250A (cg-RX-API-DMAC7.html)
CN (1) CN118541166A (cg-RX-API-DMAC7.html)
AU (1) AU2022367611A1 (cg-RX-API-DMAC7.html)
CA (1) CA3235879A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024001157A1 (cg-RX-API-DMAC7.html)
IL (1) IL312138A (cg-RX-API-DMAC7.html)
MX (1) MX2024004619A (cg-RX-API-DMAC7.html)
PE (1) PE20241351A1 (cg-RX-API-DMAC7.html)
TW (1) TW202323280A (cg-RX-API-DMAC7.html)
WO (1) WO2023061424A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4136116A4 (en) * 2020-04-17 2024-06-19 Hutchison Medipharma Limited ANTI-OX40 ANTIBODIES AND USES THEREOF
CN117257936B (zh) * 2023-10-30 2026-05-01 杭州博之锐生物制药有限公司 一种阿达木单抗组合物
WO2025185555A1 (en) * 2024-03-04 2025-09-12 Inmagene Biopharmaceuticals (Hangzhou) Co., Ltd. Pharmaceutical compositions comprising ox40 targeting antibodies and uses thereof
WO2026130530A1 (en) * 2024-12-19 2026-06-25 Akeso Biopharma Co., Ltd. Antibody formulations with reduced aggregation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100014588A (ko) * 2007-02-27 2010-02-10 제넨테크, 인크. 길항제 ox40 항체 및 염증성 및 자가면역 질환의 치료에서의 이의 용도
SG11201607969XA (en) * 2014-03-31 2016-10-28 Genentech Inc Anti-ox40 antibodies and methods of use
WO2017134292A1 (en) * 2016-02-04 2017-08-10 Glenmark Pharmaceuticals S.A. Anti-ox40 antagonistic antibodies for the treatment of atopic dermatitis
ES3014697T3 (en) * 2018-07-19 2025-04-24 Ichnos Sciences S A Liquid antibody formulation
TWI726426B (zh) * 2018-09-25 2021-05-01 大陸商信達生物製藥(蘇州)有限公司 包含抗ox40抗體的製劑、其製備方法及其用途
EP3999537A1 (en) * 2019-07-19 2022-05-25 Ichnos Sciences SA Lyophilized antibody formulation
TW202144005A (zh) * 2020-03-25 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 一種抗ox40抗體醫藥組成物及其用途

Also Published As

Publication number Publication date
CN118541166A (zh) 2024-08-23
WO2023061424A1 (en) 2023-04-20
KR20240109250A (ko) 2024-07-10
TW202323280A (zh) 2023-06-16
EP4415754A4 (en) 2025-09-24
US20250282882A1 (en) 2025-09-11
JP2024538140A (ja) 2024-10-18
CA3235879A1 (en) 2023-04-20
PE20241351A1 (es) 2024-07-03
AU2022367611A1 (en) 2024-05-02
IL312138A (en) 2024-06-01
MX2024004619A (es) 2024-07-12
EP4415754A1 (en) 2024-08-21

Similar Documents

Publication Publication Date Title
MX2024004619A (es) Formulacion farmaceutica que comprende el anticuerpo monoclonal anti-ox40.
AR111455A1 (es) Formulación estable de anticuerpo
CY1122181T1 (el) Φαρμακοτεχνικη μορφη αντισωματος
AR095396A1 (es) Formulaciones de anticuerpo
CO2017004596A2 (es) Formulación estable de proteina en solucion que contiene una alta concentracion de un anticuerpo anti-vegf
BR112016026811A2 (pt) formulação de anticorpo
ECSP21043639A (es) Formulación de solución de proteínas que contiene una alta concentración de un anticuerpo anti-vegf
EA201792273A1 (ru) Композиции, содержащие комбинацию анти-pd-1 антитела и другого антитела
MX2021009851A (es) Formulacion de anticuerpos terapeuticos.
CO2022005737A2 (es) Formulación estable de anticuerpo de integrina
AR120512A1 (es) Formulaciones que contienen anticuerpos
BR112022001775A2 (pt) Formulação compreendendo o anticorpo biespecífico anti-pd-1/her2, método para preparo e uso do mesmo
ECSP24012819A (es) Proteínas actrii y usos de las mismas
BR112015022946A2 (pt) forma de dosagem de cápsula de gelatina macia farmacêutica com goma guar modificada
BR112019025591A2 (pt) Composição farmacêutica compreendendo conjugado de fármaco-anticorpo c-met e uso do mesmo
ZA202212081B (en) Stable formulation for recombinant anti-pd-1 monoclonal antibody
CL2024003444A1 (es) Formulación farmacéutica líquida estable que comprende un anticuerpo biespecífico anti-cd20/cd3 humano.
CO2021012391A2 (es) Estabilidad api mejorada en capsulas blandas
CO2020013545A2 (es) Formulación estable de anticuerpos
MX2024004656A (es) Formulaciones acuosas de un anticuerpo anti-cd22 y usos de las mismas.
AR130115A2 (es) Formulación de solución de proteína estable que contiene alta concentración de un anticuerpo anti-vegf
AR102572A1 (es) Formulación de solución de proteína estable que contiene alta concentración de un anticuerpo anti-vegf
CL2020000356A1 (es) Composiciones farmacéuticas.
CO2023000264A2 (es) Formulaciones de anticuerpo de activina a y métodos para utilizarlas
EA201800360A1 (ru) Способ получения фармацевтической композиции, содержащей бендамустин, фармацевтическая композиция бендамустина